RxDoctor Payments Data

Amy Gonzalez

Psychiatric/Mental Health · Salt Lake City, UTNPI 1023249737

Payments from drug & device makers

$1,363in general payments, 2019–2025

Across 54 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$404
  • Johnson & Johnson$343
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$231
  • Teva Pharmaceuticals USA, Inc.$148
  • Lundbeck LLC$95
  • Vanda Pharmaceuticals Inc.$64
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$1,363100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,363 in reported general payments places this provider in the 70th percentile of 393 psychiatric/mental health providers in Utah.

See all psychiatric/mental health providers in Utah

Medicare billing

Part B allowed, 2024
$12,361
Medicare patients
26
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine12$185,308
Invega TrinzaPaliperidone Palmitate14$148,709
AustedoDeutetrabenazine12$98,075
Invega SustennaPaliperidone Palmitate33$96,829
Abilify MaintenaAripiprazole25$71,038
CaplytaLumateperone Tosylate18$32,504
RexultiBrexpiprazole21$32,465
VraylarCariprazine Hcl22$32,292
TrintellixVortioxetine Hydrobromide16$8,010
Quetiapine Fumarate99$3,127
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl42$3,065
Divalproex Sodium ErDivalproex Sodium12$2,091
Aripiprazole49$2,068
Doxepin Hcl51$1,971
Duloxetine Hcl47$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$148$283,38324 claims
Johnson & JohnsonInvega Trinza, Invega Sustenna$343$245,53847 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$20$103,50346 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$231$32,50418 claims
AbbVieVraylar$404$32,29222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 393 psychiatric/mental health providers in Utah.

Other psychiatric/mental health in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →